Sinovant Sciences of Shanghai, an offshoot of the Roivant group of biopharmas, broke from stealth mode by announcing its formation, a portfolio of eleven drug candidates for the Chinamarket and backing from CITICPE. In general, Roivant companies aim to reduce the time and cost of drug development, with each company formed around a specific goal. Earlier this year, Roivant in-licensed China rights to an FGFR inhibitor for liver cancer and a novel antibiotic, both of which are now Sinovant products.
Source: China Biotoday
